IceCure Medical Revenue and Competitors

Claim your profile

Collierville, TN USA

Location

$48M

Total Funding

Estimated Revenue & Valuation

  • IceCure Medical's estimated annual revenue is currently $22.6M per year.(i)
  • IceCure Medical received $5.5M in venture funding in February 2015.
  • IceCure Medical's estimated revenue per employee is $251,000
  • IceCure Medical's total funding is $48M.

Employee Data

  • IceCure Medical has 90 Employees.(i)
  • IceCure Medical grew their employee count by 18% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.6M45-12%N/AN/A
#2
$8.3M33-15%N/AN/A
#3
$1.3M5N/AN/AN/A
#4
$3.8M3728%N/AN/A
#5
$51M2036%N/AN/A
#6
$24.1M9622%N/AN/A
#7
$24.6M1200%N/AN/A
#8
$4.8M4648%N/AN/A
#9
$18.1M721%N/AN/A
#10
$2.8M2780%N/AN/A

IceCure Medical is a medical device company, with US operations in Collierville, TN. Our parent company, IceCure Medical, LTD was founded in 2006 and is located in Ceseara, Israel. IceCure Medical develops and markets minimally invasive cryoablation therapies for benign and malignant tumors. Our proprietary ProSense system provides a minimally invasive, in-office definitive treatment for symptomatic breast fibroadenoma. The ProSense procedure is an attractive alternative to the current standard treatment of open surgical excision. The ProSense procedure uses ultrasound imaging to guide a small probe (thin hollow needle) into the tumor. The system then uses extremely cold temperatures to destroy (ablate) the targeted tumor in-situ. The ProSense cryoablation procedure is a safe and effective treatment option that can be performed in 10-15 minutes in the comfort of a doctor's office. We are currently conducting the ICE3 Clinical trial for the non-surgical treatment of breast cancer. There are 20 sites intially participating in this trial where certain small breast cancers will be treated with cryoablation then followed for 5 years. This allows women to be treated for their breast cancer with out surgery. IceCure support of patients and physicians through its Breast Health Options advocacy program embodies its firm commitment to offer affordable care. For more information, visit www.icecure-medical.com, www.breasthealthoptions.com, and @CoverCryo on Twitter.

keywords:Biotechnology,Enterprise Software,Health It,Healthcare,Medical Devices,Pharmaceuticals

$48M

Total Funding

90

Number of Employees

$22.6M

Revenue (est)

18%

Employee Growth %

N/A

Valuation

N/A

Accelerator

IceCure Medical News

2022-04-19 - Ra Medical Systems (NYSE:RMED) and IceCure Medical (NASDAQ ...

Ra Medical Systems (NYSE:RMED) and IceCure Medical (NASDAQ:ICCM) Head to Head Analysis. Posted by admin on Apr 25th, 2022.

2022-04-17 - Reviewing IceCure Medical (NASDAQ:ICCM) and Venus Concept ...

This table compares IceCure Medical and Venus Concept's top-line revenue, earnings per share (EPS) and valuation. Gross Revenue, Price/Sales...

2022-04-17 - Financial Survey: IceCure Medical (NASDAQ:ICCM) vs. Westaim ...

Financial Survey: IceCure Medical (NASDAQ:ICCM) vs. Westaim (OTCMKTS:WEDXF). Posted by admin on Apr 23rd, 2022. Share on Twitter Share on Facebook Share on...

2021-09-01 - IceCure Medical : Announces Exclusive Distribution Agreement to Sell ProSense™ Cryoablation System in Turkey

CAESAREA, Israel, Sept. 1, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced it has entered into an initial distribution ...

2021-08-26 - IceCure Medical : Shares to Begin Trading on Nasdaq Capital Market on August 26, 2021

CAESAREA, Israel, Aug. 26, 2021 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) (TASE: ICCM) ("IceCure" or the "Company"), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that its ordinary shares have been approved ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$26.6M11721%N/A
#2
$30.8M12218%N/A
#3
$23.5M1245%N/A
#4
$18.7M13441%N/A
#5
$64.5M166-12%N/A

IceCure Medical Funding

DateAmountRoundLead InvestorsReference
2015-02-24$5.5MUndisclosedEpoch Partner InvestmentsArticle